Basit öğe kaydını göster

dc.contributor.authorDoss, W.
dc.contributor.authorVan Vlierberghe, H.
dc.contributor.authorGschwantler, M.
dc.contributor.authorAkarca, U.
dc.contributor.authorAleman, S.
dc.contributor.authorMendes Correa, M. C.
dc.contributor.authorMoreno, C.
dc.contributor.authorMuellhaupt, B.
dc.contributor.authorMyers, R. P.
dc.contributor.authorNemecek, V.
dc.contributor.authorOvrehus, A. L. H.
dc.contributor.authorParkes, J.
dc.contributor.authorPeltekian, K. M.
dc.contributor.authorRamji, A.
dc.contributor.authorRazavi, H.
dc.contributor.authorReis, N.
dc.contributor.authorRoberts, S. K.
dc.contributor.authorRoudot-Thoraval, F.
dc.contributor.authorRyder, S. D.
dc.contributor.authorSarmento-Castro, R.
dc.contributor.authorSarrazin, C.
dc.contributor.authorSemela, D.
dc.contributor.authorSherman, M.
dc.contributor.authorShiha, G. E.
dc.contributor.authorSperl, J.
dc.contributor.authorStarkel, P.
dc.contributor.authorStauber, R. E.
dc.contributor.authorThompson, A. J.
dc.contributor.authorUrbanek, P.
dc.contributor.authorVan Damme, P.
dc.contributor.authorvan Thiel, I.
dc.contributor.authorVandijck, D.
dc.contributor.authorVogel, W.
dc.contributor.authorWaked, I.
dc.contributor.authorWeis, N.
dc.contributor.authorWiegand, J.
dc.contributor.authorYosry, A.
dc.contributor.authorZekry, A.
dc.contributor.authorNegro, F.
dc.contributor.authorSievert, W.
dc.contributor.authorGower, E.
dc.contributor.authorKaymakoglu, S.
dc.contributor.authorWedemeyer, H.
dc.contributor.authorDuberg, A. S.
dc.contributor.authorButi, M.
dc.contributor.authorRosenberg, W. M.
dc.contributor.authorFrankova, S.
dc.contributor.authorEsmat, G.
dc.contributor.authorBalik, I.
dc.contributor.authorBerg, T.
dc.contributor.authorBihl, F.
dc.contributor.authorBilodeau, M.
dc.contributor.authorBlasco, A. J.
dc.contributor.authorBrandao Mello, C. E.
dc.contributor.authorBruggmann, P.
dc.contributor.authorCalinas, F.
dc.contributor.authorCalleja, J. L.
dc.contributor.authorCheinquer, H.
dc.contributor.authorChristensen, P. B.
dc.contributor.authorClausen, M.
dc.contributor.authorCoelho, H. S. M.
dc.contributor.authorCornberg, M.
dc.contributor.authorCramp, M. E.
dc.contributor.authorDore, G. J.
dc.contributor.authorOrmeci, N.
dc.contributor.authorEl-Sayed, M. H.
dc.contributor.authorErgor, G.
dc.contributor.authorEstes, C.
dc.contributor.authorFalconer, K.
dc.contributor.authorFelix, J.
dc.contributor.authorFerraz, M. L. G.
dc.contributor.authorFerreira, P. R.
dc.contributor.authorGarcia-Samaniego, J.
dc.contributor.authorGerstoft, J.
dc.contributor.authorGiria, J. A.
dc.contributor.authorGoncales, F. L.
dc.contributor.authorGuimaraes Pessoa, M.
dc.contributor.authorHezode, C.
dc.contributor.authorHindman, S. J.
dc.contributor.authorHofer, H.
dc.contributor.authorHusa, P.
dc.contributor.authorIdilman, R.
dc.contributor.authorKaberg, M.
dc.contributor.authorKaita, K. D. E.
dc.contributor.authorKautz, A.
dc.contributor.authorKrajden, M.
dc.contributor.authorKrarup, H.
dc.contributor.authorLaleman, W.
dc.contributor.authorLavanchy, D.
dc.contributor.authorLazaro, P.
dc.contributor.authorMarinho, R. T.
dc.contributor.authorMarotta, P.
dc.contributor.authorMauss, S.
dc.date.accessioned2021-03-05T08:25:19Z
dc.date.available2021-03-05T08:25:19Z
dc.identifier.citationWedemeyer H., Duberg A. S. , Buti M., Rosenberg W. M. , Frankova S., Esmat G., Ormeci N., Van Vlierberghe H., Gschwantler M., Akarca U., et al., "Strategies to manage hepatitis C virus (HCV) disease burden", JOURNAL OF VIRAL HEPATITIS, cilt.21, ss.60-89, 2014
dc.identifier.issn1352-0504
dc.identifier.otherav_98ca47f5-5adc-46c9-b0eb-124d9a479bd8
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/102800
dc.identifier.urihttps://doi.org/10.1111/jvh.12249
dc.description.abstractThe number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.
dc.language.isoeng
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectMikrobiyoloji ve Klinik Mikrobiyoloji
dc.subjectViroloji
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectGastroenteroloji-(Hepatoloji)
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectGASTROENTEROLOJİ VE HEPATOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectBULAŞICI HASTALIKLAR
dc.subjectİmmünoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectVİROLOJİ
dc.titleStrategies to manage hepatitis C virus (HCV) disease burden
dc.typeMakale
dc.relation.journalJOURNAL OF VIRAL HEPATITIS
dc.contributor.departmentHannover Medical School , ,
dc.identifier.volume21
dc.identifier.startpage60
dc.identifier.endpage89
dc.contributor.firstauthorID214676


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster